File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Serum Hepatitis B Surface Antigen Levels To Guide The Cessation Of Entecavir In Hepatitis B E Antigen-Negative Chronic Hepatitis B: An Interim Analysis

TitleSerum Hepatitis B Surface Antigen Levels To Guide The Cessation Of Entecavir In Hepatitis B E Antigen-Negative Chronic Hepatitis B: An Interim Analysis
Authors
Issue Date2013
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands, 24-28 April 2013. In Journal of Hepatology, 2013, v. 58 n. Suppl. 1, p. S315, abstract no. 773 How to Cite?
AbstractBackground: Cessation of nucleoside analogue therapy in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is controversial. It is uncertain whether serum hepatitis B surface antigen (HBsAg) levels can predict virologic kinetics after treatment cessation. Methods: Entecavir was stopped in HBeAg-negative patients treated for at least 2 years with no co-existing or decompensated liver disease. All patients had undetectable HBV DNA levels on at least 3 separate occasions 6 months apart before treatment cessation. Serum HBsAg (Elecsys II, lower limit of detection 0.05 IU/mL), HBV DNA (Cobas Taqman, lower limit of detection 20 IU/mL) and liver biochemistry were monitored at every 6–12 weeks for 1 year. Entecavir was restarted if virologic relapse, defined as HBV DNA >2,000 IU/mL occurred. The primary endpoint was sustained virologic remission, defined as HBV DNA persistently ≤200 IU/mL. Results: 184 patients (median age 54 years, 67.9% male) were recruited. The median baseline HBsAg level was 892 (range 2.3–24,100) IU/mL. Median duration of entecavir therapy before cessation was 3.05 (range 2.02–5.95) years. At the time of writing, 158 (85.9%) and 104 (56.2%) patients have been followed up for 12 and 24 weeks respectively. The cumulative rates of virologic relapse, calculated using the Kaplan–Meier method, were 11.2% at week 12 and 78.1% at week 24 respectively. Among patients with 24 weeks of follow-up (n = 104), patients achieving sustained virologic remission (n = 9), when compared to patients without virologic remission (n = 93) had a significantly longer median duration of entecavir treatment before therapy cessation (4.05 and 3.03 years respectively, p = 0.007), a higher probability of undetectable viremia at week 12 (88.9% and 17.9% respectively, p<0.001) and a trend towards a lower median baseline HBsAg level (701 and 936 IU/mL respectively, p = 0.088). Conclusion: Base on this interim analysis, a longer duration of prior nucleoside analogue therapy and off-treatment HBV DNA undetectability at week 12 were associated with a higher chance of sustained virologic remission after treatment cessation. Subsequent analysis would determine if baseline and off-treatment HBsAg levels could predict virologic remission after treatment cessation. Acknowledgement: This study was supported by an unrestricted grant from Roche Diagnostics
DescriptionFulltext in: http://www2.kenes.com/liver-congress/scientific/Documents/Abstract_book.pdf
Poster Session: 07c. Viral Hepatitis B & D: Clinical (Therapy, New Compounds, Resistance)
Persistent Identifierhttp://hdl.handle.net/10722/186828
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKWen_US
dc.contributor.authorHui, AJen_US
dc.contributor.authorWong, VWSen_US
dc.contributor.authorWong, GLHen_US
dc.contributor.authorLiu, Ken_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYuen, RMFen_US
dc.contributor.authorChan, HLYen_US
dc.date.accessioned2013-08-20T12:21:10Z-
dc.date.available2013-08-20T12:21:10Z-
dc.date.issued2013en_US
dc.identifier.citationThe 48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands, 24-28 April 2013. In Journal of Hepatology, 2013, v. 58 n. Suppl. 1, p. S315, abstract no. 773en_US
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/186828-
dc.descriptionFulltext in: http://www2.kenes.com/liver-congress/scientific/Documents/Abstract_book.pdf-
dc.descriptionPoster Session: 07c. Viral Hepatitis B & D: Clinical (Therapy, New Compounds, Resistance)-
dc.description.abstractBackground: Cessation of nucleoside analogue therapy in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is controversial. It is uncertain whether serum hepatitis B surface antigen (HBsAg) levels can predict virologic kinetics after treatment cessation. Methods: Entecavir was stopped in HBeAg-negative patients treated for at least 2 years with no co-existing or decompensated liver disease. All patients had undetectable HBV DNA levels on at least 3 separate occasions 6 months apart before treatment cessation. Serum HBsAg (Elecsys II, lower limit of detection 0.05 IU/mL), HBV DNA (Cobas Taqman, lower limit of detection 20 IU/mL) and liver biochemistry were monitored at every 6–12 weeks for 1 year. Entecavir was restarted if virologic relapse, defined as HBV DNA >2,000 IU/mL occurred. The primary endpoint was sustained virologic remission, defined as HBV DNA persistently ≤200 IU/mL. Results: 184 patients (median age 54 years, 67.9% male) were recruited. The median baseline HBsAg level was 892 (range 2.3–24,100) IU/mL. Median duration of entecavir therapy before cessation was 3.05 (range 2.02–5.95) years. At the time of writing, 158 (85.9%) and 104 (56.2%) patients have been followed up for 12 and 24 weeks respectively. The cumulative rates of virologic relapse, calculated using the Kaplan–Meier method, were 11.2% at week 12 and 78.1% at week 24 respectively. Among patients with 24 weeks of follow-up (n = 104), patients achieving sustained virologic remission (n = 9), when compared to patients without virologic remission (n = 93) had a significantly longer median duration of entecavir treatment before therapy cessation (4.05 and 3.03 years respectively, p = 0.007), a higher probability of undetectable viremia at week 12 (88.9% and 17.9% respectively, p<0.001) and a trend towards a lower median baseline HBsAg level (701 and 936 IU/mL respectively, p = 0.088). Conclusion: Base on this interim analysis, a longer duration of prior nucleoside analogue therapy and off-treatment HBV DNA undetectability at week 12 were associated with a higher chance of sustained virologic remission after treatment cessation. Subsequent analysis would determine if baseline and off-treatment HBsAg levels could predict virologic remission after treatment cessation. Acknowledgement: This study was supported by an unrestricted grant from Roche Diagnostics-
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatologyen_US
dc.titleSerum Hepatitis B Surface Antigen Levels To Guide The Cessation Of Entecavir In Hepatitis B E Antigen-Negative Chronic Hepatitis B: An Interim Analysisen_US
dc.typeConference_Paperen_US
dc.identifier.emailSeto, WKW: wkseto2@hku.hken_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailYuen, RMF: mfyuen@hku.hken_US
dc.identifier.authoritySeto, WKW=rp01659en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.doi10.1016/S0168-8278(13)60775-8-
dc.identifier.hkuros218447en_US
dc.identifier.volume58en_US
dc.identifier.issueSuppl. 1en_US
dc.identifier.spageS315, abstract no. 773en_US
dc.identifier.epageS315, abstract no. 773en_US
dc.publisher.placeNetherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats